Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit... Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity.
- Mechanism
- Curator reviewed
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.Curator reviewed
- Code names
- TRX4
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Otelixizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account